NSE:SANOFICONR Research Reports

Sanofi Consumer Healthcare India is a pure-play consumer health company built on a simple idea - that everyday ailments like allergies, pain, and vitamin deficiencies are better managed with science-backed remedies people can choose for themselves, not just ones a doctor prescribes. It was carved out of Sanofi India Limited and listed in September 2024 as part of a global move to create a standalone consumer healthcare giant, Opella, now controlled by private equity firm CD&R. The recurring approach is to take trusted legacy brands that had been starved of investment for years, reactivate them with the marketing muscle and retail push of a fast-moving consumer goods company, and grow the entire self-care category by teaching consumers the difference between a cold and an allergy, or why Vitamin D matters.

Business segments

A single consumer healthcare engine organised around four therapeutic categories - Allergy, Pain, Physical Wellness, and Digestive Health - all pushed through the same rebuilt go-to-market machinery.

1. Allergy Care: the category leader that teaches consumers what to buy

Two legacy antihistamine brands, Allegra and Avil, together bring in over half the company's revenue and hold the top spots by volume in a market where nearly a third of Indians suffer from allergies but few seek treatment.

#1 by volume for over 15 years - Allegra is a non-drowsy antihistamine for sneezing, runny nose, and itchy eyes, and has led the allergy oral category by volume for more than a decade and a half, with a 7% value share as of December 2025.
The injectable that dominates - Avil is an injectable antihistamine used for everything from hay fever and drug rashes to motion sickness and vertigo; it is the #1 volume player in the allergy category with a 6.5% value share, so together the two brands command a 9% share of a ₹5,241 crore market.
First-mover in consumer education - the company positions itself as the one teaching consumers basic distinctions like common cold versus allergy, because roughly 30-40% of the population suffers from allergy-related conditions but awareness and treatment levels remain low.

2. Pain Care: the dormant giant reactivated

Combiflam sold over 62 million tablets a year without any doctor promotion for 15 years - now that the sales force is back in clinics, the brand is being pushed across all three demand levers for the first time.

A top-5 brand on residual trust alone - Combiflam, an ibuprofen-plus-paracetamol combination for headaches, body aches, and fever, ranks #5 by volume in the pain category, despite zero HCP promotion for a decade and a half before the demerger.
A children's line and a topical cream - the portfolio now includes Combiflam oral suspension for children aged six months and above, relaunched in June 2025, and Combiflam MS Cream for topical pain relief, whose launch campaign at Mumbai's Lalbaugcha Raja won two national awards for experiential marketing.
Nine in ten Indians are in pain - the pain category is sized at ₹9,399 crore, and roughly 90% of Indians have experienced a pain episode, so the addressable market is vast even with a modest share.

3. Physical Wellness: the Vitamin D play in a deficient nation

DePURA is a top-5 Vitamin D3 brand in a country where roughly seven in ten people are deficient, rebuilt from a voluntary recall into a fully active brand across all demand levers.

A top-5 brand in a ₹1,469 crore category - DePURA holds a 1.8% value share in the Vitamin D market, with two stock-keeping units: a 60,000 IU adult dose and a kids' drops formulation.
Social media is the biggest influencer - for vitamins and supplements, consumers are influenced first by social media, then by doctors and dieticians, and only then by their own research, which is why the company runs digital-first campaigns alongside HCP detailing.
Award-winning awareness push - DePURA's Vitamin D awareness campaign won industry recognition, and the brand is now active on the HCP demand-generation lever.

4. Digestive Health: the small enzyme-based niche

A minor category contributing 3% of revenue, anchored by Festal N, an enzyme-based digestive aid, with limited operational detail disclosed.

Enzyme-based digestive solution - Festal N is the named product in this category, which sits alongside other minor products to make up the 3% revenue contribution in FY26.
Broader digestive wellness scope - filings reference a wider Digestive Wellness portfolio, but no further product names, market shares, or go-to-market specifics are available.

Go-to-Market & Demand Generation

A three-lever engine - doctors, consumers, and chemists - rebuilt from scratch after the demerger, because the legacy pharma model had no consumer advertising and no direct retail push.

HCP detailing doubled in a year - the company uses both face-to-face visits and digital outreach to engage healthcare professionals, doubling its in-person doctor reach during FY26 and extending digital engagement to over 50,000 HCPs, though its coverage is still only about a third to half that of peers.
Digital-first consumer campaigns at a fraction of peer spend - media investments reached roughly 60 million consumers across core categories during FY26, with targeted social media spending aimed at driving about 30% influence, yet total media spends are less than one-tenth of the top spender in the category.
Direct retail coverage doubled - the company moved from a largely indirect distribution model, where products reached stores through wholesalers, to one with direct control over roughly 0.4x the store coverage of peers, enabling range selling rather than just availability.
The 50-30-20 purchase split - in consumer healthcare, roughly half of purchase decisions are influenced by doctors, 30% by direct-to-consumer channels, and 20% by chemists, which is why the three-lever model is designed to hit all three simultaneously.
2,980 dealers and counting - sales are 100% through dealers and distributors, reaching consumers via stockists, wholesalers, government institutions, modern pharmacy chains, and e-commerce platforms, with the top 10 dealers representing about 31% of total dealer sales in CY2025.

Supply Chain & Operations

An asset-light, almost entirely outsourced manufacturing model with zero owned plants, producing nearly everything in India through local partners.

Zero factories, full control - almost 100% of production happens in India through strategic local manufacturing partners, giving the company independence from global supply chains and full control over stock availability.
Exports began in 2025 - the company started exporting finished goods to Opella Healthcare International SAS, with exports contributing 19% of total turnover and serving four international countries.
World-class pharma quality without owning plants - products are manufactured to pharmaceutical quality standards by local partners, and the company transacts with Sanofi India Limited for toll manufacturing and support services where needed to leverage existing licences.

Digital, AI & Technology

A dedicated in-house AI team and a proprietary field-force platform give the company faster creative turnaround and real-time decision-making at the last mile, without waiting for global approvals.

In-house AI creative team - the company built its own AI creative unit for India, enabling rapid production of marketing creatives in local languages without needing sign-off from global headquarters.
One Touch platform for the field force - every sales representative is equipped with a proprietary tool that provides real-time data and AI-led prescriptive analysis, so decisions at the pharmacy counter are faster and sharper.
India-first brand control - the company has complete ownership of global brand profit-and-loss at the country level, which means it can make faster decisions and pilot India-first innovations while still benefiting from Opella's global R&D and technology scale.

Group structure and partners

SCHIL is a publicly listed subsidiary of Opella, the world's third-largest OTC and VMS business, in which private equity firm CD&R holds a controlling stake - giving it the backing of a global consumer health giant with an empowered local management.

Two promoters, one controlling shareholder - as of FY26, Opella Healthcare Participations B.V. holds 60.40% and Opal Bidco SAS (a CD&R entity) holds 28.73%, with public shareholders at 10.87%; there are no subsidiaries, associates, or joint ventures.
The CD&R transaction - in October 2024, Sanofi and CD&R entered exclusive negotiations for CD&R to acquire a controlling stake in Opella; the deal closed on 30th April 2025 with Sanofi selling a 50% controlling stake for around €10 billion in net cash proceeds, while retaining a 48.2% stake alongside Bpifrance at 1.8%.
Mandatory open offer - the change in control triggered an open offer to public shareholders at ₹4,982.05 per share; about 42% of the offer size was tendered, and Opal Bidco SAS acquired those shares in June 2025, taking the combined promoter holding to 71.27%.
Opella's global scale - the parent entity is headquartered in France, employs over 11,000 people across 100 countries, operates 13 manufacturing sites and four R&D centres, and serves over half a billion consumers with brands including Allegra, Doliprane, and Dulcolax.
Operational ties with group entities - SCHIL provides consignment agency and business support services to Opella Healthcare India Private Limited, exports to and buys from Opella SAS, and transacts with Sanofi India Limited for toll manufacturing and support services, creating a web of intra-group operational linkages.

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	210	225	222	172	160	171	173	221	234	251	229	236
Growth YoY Revenue Growth YoY%					-24.0	-24.0	-22.1	28.2	46.3	47.0	32.8	6.7
Expenses ExpensesCr	116	135	140	109	97	109	109	151	149	161	140	146
Operating Profit Operating ProfitCr	95	90	82	64	63	62	64	70	85	90	89	89
OPM OPM%	45.0	39.9	36.9	36.9	39.5	36.4	37.1	31.8	36.3	35.8	38.7	37.9
Other Income Other IncomeCr	1	1	3	-24	3	2	5	12	3	5	6	6
Interest Expense Interest ExpenseCr	0	0	0	0	3	0	0	1	1	1	1	0
Depreciation DepreciationCr	1	1	1	1	2	1	2	3	3	3	3	3
PBT PBTCr	95	90	84	39	61	63	67	79	84	91	91	92
Tax TaxCr	24	22	21	10	16	19	17	18	21	24	23	23
PAT PATCr	71	68	63	29	45	44	50	61	63	67	68	69
Growth YoY PAT Growth YoY%					-36.8	-34.8	-20.3	109.3	39.8	50.1	35.6	13.3
NPM NPM%	33.9	30.2	28.3	16.8	28.1	25.9	29.0	27.5	26.9	26.5	29.6	29.2
EPS EPS₹	30.9	30.3	27.2	23.1	19.5	19.3	21.7	26.4	27.3	28.9	29.4	29.9

Quarter

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

Revenue

RevenueCr

210

225

222

172

160

171

173

221

234

251

229

236

Growth YoY

Revenue Growth YoY%

-24.0

-22.1

28.2

46.3

47.0

32.8

6.7

Expenses

ExpensesCr

116

135

140

109

151

149

161

140

146

Operating Profit

Operating ProfitCr

OPM

OPM%

45.0

39.9

36.9

39.5

36.4

37.1

31.8

36.3

35.8

38.7

37.9

Other Income

Other IncomeCr

-24

Interest Expense

Interest ExpenseCr

Depreciation

DepreciationCr

PBT

PBTCr

Tax

TaxCr

PAT

PATCr

Growth YoY

PAT Growth YoY%

-36.8

-34.8

-20.3

109.3

39.8

50.1

35.6

13.3

NPM

NPM%

33.9

30.2

28.3

16.8

28.1

25.9

29.0

27.5

26.9

26.5

29.6

29.2

EPS

EPS₹

30.9

30.3

27.2

23.1

19.5

19.3

21.7

26.4

27.3

28.9

29.4

29.9

Quarter	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue RevenueCr	210	225	222	172	160	171	173	221	234	251	229	236
Growth YoY Revenue Growth YoY%					-24.0	-24.0	-22.1	28.2	46.3	47.0	32.8	6.7
Expenses ExpensesCr	116	135	140	109	97	109	109	151	149	161	140	146
Operating Profit Operating ProfitCr	95	90	82	64	63	62	64	70	85	90	89	89
OPM OPM%	45.0	39.9	36.9	36.9	39.5	36.4	37.1	31.8	36.3	35.8	38.7	37.9
Other Income Other IncomeCr	1	1	3	-24	3	2	5	12	3	5	6	6
Interest Expense Interest ExpenseCr	0	0	0	0	3	0	0	1	1	1	1	0
Depreciation DepreciationCr	1	1	1	1	2	1	2	3	3	3	3	3
PBT PBTCr	95	90	84	39	61	63	67	79	84	91	91	92
Tax TaxCr	24	22	21	10	16	19	17	18	21	24	23	23
PAT PATCr	71	68	63	29	45	44	50	61	63	67	68	69
Growth YoY PAT Growth YoY%					-36.8	-34.8	-20.3	109.3	39.8	50.1	35.6	13.3
NPM NPM%	33.9	30.2	28.3	16.8	28.1	25.9	29.0	27.5	26.9	26.5	29.6	29.2
EPS EPS₹	30.9	30.3	27.2	23.1	19.5	19.3	21.7	26.4	27.3	28.9	29.4	29.9

Quarter

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

Revenue

RevenueCr

210

225

222

172

160

171

173

221

234

251

229

236

Growth YoY

Revenue Growth YoY%

-24.0

-22.1

28.2

46.3

47.0

32.8

6.7

Expenses

ExpensesCr

116

135

140

109

151

149

161

140

146

Operating Profit

Operating ProfitCr

OPM

OPM%

45.0

39.9

36.9

39.5

36.4

37.1

31.8

36.3

35.8

38.7

37.9

Other Income

Other IncomeCr

-24

Interest Expense

Interest ExpenseCr

Depreciation

DepreciationCr

PBT

PBTCr

Tax

TaxCr

PAT

PATCr

Growth YoY

PAT Growth YoY%

-36.8

-34.8

-20.3

109.3

39.8

50.1

35.6

13.3

NPM

NPM%

33.9

30.2

28.3

16.8

28.1

25.9

29.0

27.5

26.9

26.5

29.6

29.2

EPS

EPS₹

30.9

30.3

27.2

23.1

19.5

19.3

21.7

26.4

27.3

28.9

29.4

29.9

Financial Year	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Dec 2025	TTM
Revenue RevenueCr	555	725	725	878	878	950
Growth Revenue Growth%			30.4	21.2	21.2	31.2
Expenses ExpensesCr	337	454	454	569	569	597
Operating Profit Operating ProfitCr	219	271	271	309	309	353
OPM OPM%	39.4	37.4	37.4	35.2	35.2	37.2
Other Income Other IncomeCr	2		-15		25	20
Interest Expense Interest ExpenseCr	0	4	4	2	2	2
Depreciation DepreciationCr	2	5	5	12	12	13
PBT PBTCr	219	247	247	320	320	357
Tax TaxCr	54	66	66	80	80	91
PAT PATCr	165	181	181	240	240	266
Growth PAT Growth%			9.8	32.6	32.6	33.0
NPM NPM%	29.7	25.0	25.0	27.3	27.3	28.0
EPS EPS₹	71.6		78.6	104.3	104.3	115.5

Financial Year

Dec 2023

Mar 2024

Dec 2024

Mar 2025

Dec 2025

TTM

Revenue

RevenueCr

555

725

878

950

Growth

Revenue Growth%

30.4

21.2

31.2

Expenses

ExpensesCr

337

454

569

597

Operating Profit

Operating ProfitCr

219

271

309

353

OPM

OPM%

39.4

37.4

35.2

37.2

Other Income

Other IncomeCr

-15

Interest Expense

Interest ExpenseCr

Depreciation

DepreciationCr

PBT

PBTCr

219

247

320

357

Tax

TaxCr

PAT

PATCr

165

181

240

266

Growth

PAT Growth%

9.8

32.6

33.0

NPM

NPM%

29.7

25.0

27.3

28.0

EPS

EPS₹

71.6

78.6

104.3

115.5

Financial Year	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Dec 2025	TTM
Revenue RevenueCr	555	725	725	878	878	950
Growth Revenue Growth%			30.4	21.2	21.2	31.2
Expenses ExpensesCr	337	454	454	569	569	597
Operating Profit Operating ProfitCr	219	271	271	309	309	353
OPM OPM%	39.4	37.4	37.4	35.2	35.2	37.2
Other Income Other IncomeCr	2		-15		25	20
Interest Expense Interest ExpenseCr	0	4	4	2	2	2
Depreciation DepreciationCr	2	5	5	12	12	13
PBT PBTCr	219	247	247	320	320	357
Tax TaxCr	54	66	66	80	80	91
PAT PATCr	165	181	181	240	240	266
Growth PAT Growth%			9.8	32.6	32.6	33.0
NPM NPM%	29.7	25.0	25.0	27.3	27.3	28.0
EPS EPS₹	71.6		78.6	104.3	104.3	115.5

Financial Year

Dec 2023

Mar 2024

Dec 2024

Mar 2025

Dec 2025

TTM

Revenue

RevenueCr

555

725

878

950

Growth

Revenue Growth%

30.4

21.2

31.2

Expenses

ExpensesCr

337

454

569

597

Operating Profit

Operating ProfitCr

219

271

309

353

OPM

OPM%

39.4

37.4

35.2

37.2

Other Income

Other IncomeCr

-15

Interest Expense

Interest ExpenseCr

Depreciation

DepreciationCr

PBT

PBTCr

219

247

320

357

Tax

TaxCr

PAT

PATCr

165

181

240

266

Growth

PAT Growth%

9.8

32.6

33.0

NPM

NPM%

29.7

25.0

27.3

28.0

EPS

EPS₹

71.6

78.6

104.3

115.5

Financial Year	Dec 2023	Dec 2024	Dec 2025
Equity Capital Equity CapitalCr	2	23	23
Reserves ReservesCr	183	250	361
Current Liabilities Current LiabilitiesCr	130	131	128
Non Current Liabilities Non Current LiabilitiesCr	8	28	35
Total Liabilities Total LiabilitiesCr	345	431	547
Current Assets Current AssetsCr	335	392	494
Non Current Assets Non Current AssetsCr	10	40	53
Total Assets Total AssetsCr	345	431	547

Financial Year

Dec 2023

Dec 2024

Dec 2025

Equity Capital

Equity CapitalCr

Reserves

ReservesCr

183

250

361

Current Liabilities

Current LiabilitiesCr

130

131

128

Non Current Liabilities

Non Current LiabilitiesCr

Total Liabilities

Total LiabilitiesCr

345

431

547

Current Assets

Current AssetsCr

335

392

494

Non Current Assets

Non Current AssetsCr

Total Assets

Total AssetsCr

345

431

547

Financial Year	Dec 2023	Dec 2024	Dec 2025
Equity Capital Equity CapitalCr	2	23	23
Reserves ReservesCr	183	250	361
Current Liabilities Current LiabilitiesCr	130	131	128
Non Current Liabilities Non Current LiabilitiesCr	8	28	35
Total Liabilities Total LiabilitiesCr	345	431	547
Current Assets Current AssetsCr	335	392	494
Non Current Assets Non Current AssetsCr	10	40	53
Total Assets Total AssetsCr	345	431	547

Financial Year

Dec 2023

Dec 2024

Dec 2025

Equity Capital

Equity CapitalCr

Reserves

ReservesCr

183

250

361

Current Liabilities

Current LiabilitiesCr

130

131

128

Non Current Liabilities

Non Current LiabilitiesCr

Total Liabilities

Total LiabilitiesCr

345

431

547

Current Assets

Current AssetsCr

335

392

494

Non Current Assets

Non Current AssetsCr

Total Assets

Total AssetsCr

345

431

547

Financial Year	Dec 2023	Mar 2024	Dec 2024	Dec 2025
Operating Cash Flow Operating Cash FlowCr	0	439	439	175
Investing Cash Flow Investing Cash FlowCr	0	2	2	8
Financing Cash Flow Financing Cash FlowCr	2	-116	-116	-135
Net Cash Flow Net Cash FlowCr	2	325	325	48
Free Cash Flow Free Cash FlowCr	-4		429	167
CFO To PAT CFO To PAT%	-0.2	242.5	242.5	72.8
CFO To EBITDA CFO To EBITDA%	-0.2	162.2	162.2	56.6

Financial Year

Dec 2023

Mar 2024

Dec 2024

Dec 2025

Operating Cash Flow

Operating Cash FlowCr

439

175

Investing Cash Flow

Investing Cash FlowCr

Financing Cash Flow

Financing Cash FlowCr

-116

-135

Net Cash Flow

Net Cash FlowCr

325

Free Cash Flow

Free Cash FlowCr

-4

429

167

CFO To PAT

CFO To PAT%

-0.2

242.5

72.8

CFO To EBITDA

CFO To EBITDA%

-0.2

162.2

56.6

Financial Year	Dec 2023	Mar 2024	Dec 2024	Dec 2025
Operating Cash Flow Operating Cash FlowCr	0	439	439	175
Investing Cash Flow Investing Cash FlowCr	0	2	2	8
Financing Cash Flow Financing Cash FlowCr	2	-116	-116	-135
Net Cash Flow Net Cash FlowCr	2	325	325	48
Free Cash Flow Free Cash FlowCr	-4		429	167
CFO To PAT CFO To PAT%	-0.2	242.5	242.5	72.8
CFO To EBITDA CFO To EBITDA%	-0.2	162.2	162.2	56.6

Financial Year

Dec 2023

Mar 2024

Dec 2024

Dec 2025

Operating Cash Flow

Operating Cash FlowCr

439

175

Investing Cash Flow

Investing Cash FlowCr

Financing Cash Flow

Financing Cash FlowCr

-116

-135

Net Cash Flow

Net Cash FlowCr

325

Free Cash Flow

Free Cash FlowCr

-4

429

167

CFO To PAT

CFO To PAT%

-0.2

242.5

72.8

CFO To EBITDA

CFO To EBITDA%

-0.2

162.2

56.6

Financial Year	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Dec 2025	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr			11,348		10,424	7,999
Price To Earnings Price To Earnings			62.6		43.4	30.1
Price To Sales Price To Sales			15.7		11.9	8.4
Price To Book Price To Book			41.5		27.1	23.0
EV To EBITDA EV To EBITDA			40.8		32.6	21.8
Profitability Ratios Profitability Ratios
GPM GPM%	64.9		68.2		67.8	67.8
OPM OPM%	39.4	37.4	37.4	35.2	35.2	37.2
NPM NPM%	29.7	25.0	25.0	27.3	27.3	28.0
ROCE ROCE%	118.8		85.5		78.8	78.8
ROE ROE%	89.3		66.3		62.5	62.5
ROA ROA%	47.7		42.0		43.9	43.9
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year

Dec 2023

Mar 2024

Dec 2024

Mar 2025

Dec 2025

Current

Valuation Ratios

Market Cap

Market CapitalizationCr

11,348

10,424

7,999

Price To Earnings

62.6

43.4

30.1

Price To Sales

15.7

11.9

8.4

Price To Book

41.5

27.1

23.0

EV To EBITDA

40.8

32.6

21.8

Profitability Ratios

GPM

GPM%

64.9

68.2

67.8

OPM

OPM%

39.4

37.4

35.2

37.2

NPM

NPM%

29.7

25.0

27.3

28.0

ROCE

ROCE%

118.8

85.5

78.8

ROE

ROE%

89.3

66.3

62.5

ROA

ROA%

47.7

42.0

43.9

Operational Ratios

Solvency Ratios

Liquidity Ratios

Financial Year	Dec 2023	Mar 2024	Dec 2024	Mar 2025	Dec 2025	Current
Valuation Ratios Valuation Ratios
Market Cap Market CapitalizationCr			11,348		10,424	7,999
Price To Earnings Price To Earnings			62.6		43.4	30.1
Price To Sales Price To Sales			15.7		11.9	8.4
Price To Book Price To Book			41.5		27.1	23.0
EV To EBITDA EV To EBITDA			40.8		32.6	21.8
Profitability Ratios Profitability Ratios
GPM GPM%	64.9		68.2		67.8	67.8
OPM OPM%	39.4	37.4	37.4	35.2	35.2	37.2
NPM NPM%	29.7	25.0	25.0	27.3	27.3	28.0
ROCE ROCE%	118.8		85.5		78.8	78.8
ROE ROE%	89.3		66.3		62.5	62.5
ROA ROA%	47.7		42.0		43.9	43.9
Operational Ratios Operational Ratios
Solvency Ratios Solvency Ratios
Liquidity Ratios Liquidity Ratios

Financial Year

Dec 2023

Mar 2024

Dec 2024

Mar 2025

Dec 2025

Current

Valuation Ratios

Market Cap

Market CapitalizationCr

11,348

10,424

7,999

Price To Earnings

62.6

43.4

30.1

Price To Sales

15.7

11.9

8.4

Price To Book

41.5

27.1

23.0

EV To EBITDA

40.8

32.6

21.8

Profitability Ratios

GPM

GPM%

64.9

68.2

67.8

OPM

OPM%

39.4

37.4

35.2

37.2

NPM

NPM%

29.7

25.0

27.3

28.0

ROCE

ROCE%

118.8

85.5

78.8

ROE

ROE%

89.3

66.3

62.5

ROA

ROA%

47.7

42.0

43.9

Operational Ratios

Solvency Ratios

Liquidity Ratios

	GLAXO	PFIZER	ASTRAZEN	PGHL	SANOFICONR	SANOFI	NOVARTIND
Market CapitalizationMkt CapCr	42,368	17,409	15,185	8,565	7,999	6,626	4,740
Close PriceClose₹	2,501.00	3,805.50	6,074.00	5,160.00	3,473.40	2,877.00	1,919.80
IndustryIndustry	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs
Price To EarningsPE	40.33	23.68	89.52	24.00	30.08	20.46	48.47
Price To SalesPS	10.71	6.77	6.24	5.98	8.42	3.67	12.79
RevenueRevenueCr	3,955	2,570	2,432	1,433	950	1,805	371
Revenue Growth TTMRev Gr TTM%	5.8%	10.7%	31.1%	12.6%	31.2%	-8.9%	5.4%
PAT Growth TTMPAT Gr TTM%	12.4%	-9.1%	-7.5%	18.7%	33.0%	-10.7%	-4.9%

Market CapitalizationMkt CapCr

42,368

17,409

15,185

8,565

7,999

6,626

4,740

Close PriceClose₹

2,501.00

3,805.50

6,074.00

5,160.00

3,473.40

2,877.00

1,919.80

IndustryIndustry

Pharma MNC Bulk Drugs

Price To EarningsPE

40.33

23.68

89.52

24.00

30.08

20.46

48.47

Price To SalesPS

10.71

6.77

6.24

5.98

8.42

3.67

12.79

RevenueRevenueCr

3,955

2,570

2,432

1,433

950

1,805

371

Revenue Growth TTMRev Gr TTM%

5.8%

10.7%

31.1%

12.6%

31.2%

-8.9%

5.4%

PAT Growth TTMPAT Gr TTM%

12.4%

-9.1%

-7.5%

18.7%

33.0%

-10.7%

-4.9%

	GLAXO	PFIZER	ASTRAZEN	PGHL	SANOFICONR	SANOFI	NOVARTIND
Market CapitalizationMkt CapCr	42,368	17,409	15,185	8,565	7,999	6,626	4,740
Close PriceClose₹	2,501.00	3,805.50	6,074.00	5,160.00	3,473.40	2,877.00	1,919.80
IndustryIndustry	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs	Pharma MNC Bulk Drugs
Price To EarningsPE	40.33	23.68	89.52	24.00	30.08	20.46	48.47
Price To SalesPS	10.71	6.77	6.24	5.98	8.42	3.67	12.79
RevenueRevenueCr	3,955	2,570	2,432	1,433	950	1,805	371
Revenue Growth TTMRev Gr TTM%	5.8%	10.7%	31.1%	12.6%	31.2%	-8.9%	5.4%
PAT Growth TTMPAT Gr TTM%	12.4%	-9.1%	-7.5%	18.7%	33.0%	-10.7%	-4.9%

Market CapitalizationMkt CapCr

42,368

17,409

15,185

8,565

7,999

6,626

4,740

Close PriceClose₹

2,501.00

3,805.50

6,074.00

5,160.00

3,473.40

2,877.00

1,919.80

IndustryIndustry

Pharma MNC Bulk Drugs

Price To EarningsPE

40.33

23.68

89.52

24.00

30.08

20.46

48.47

Price To SalesPS

10.71

6.77

6.24

5.98

8.42

3.67

12.79

RevenueRevenueCr

3,955

2,570

2,432

1,433

950

1,805

371

Revenue Growth TTMRev Gr TTM%

5.8%

10.7%

31.1%

12.6%

31.2%

-8.9%

5.4%

PAT Growth TTMPAT Gr TTM%

12.4%

-9.1%

-7.5%

18.7%

33.0%

-10.7%

-4.9%

Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Ltd

Quick Ratios

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Peer Comparison